Core Insights - CareCloud, Inc. will release its financial results for the second quarter ended June 30, 2025, before the market opens on August 5, 2025 [1] - A conference call for investors will follow at 8:30 a.m. Eastern Time on the same day [1] Company Overview - CareCloud is a leader in AI-powered healthcare technology and revenue cycle management solutions, serving medical practices and health systems across the nation [1] - The company offers a suite of solutions aimed at improving financial and operational performance, streamlining clinical workflows, and enhancing patient experience [4] - More than 40,000 providers rely on CareCloud to improve patient care while reducing administrative burdens and operating costs [4]

This AI Founder Became A Billionaire By Building ChatGPT For Doctors https://t.co/BOlZ5TfypI https://t.co/BOlZ5TfypI ...

Core Insights - HealthLynked Corp. has engaged Meridian Group to identify and secure strategic partnerships aimed at accelerating the adoption of its healthcare platform, increasing revenue, and positioning the company for long-term growth, including a potential uplisting to the Nasdaq Capital Market [1][4]. Company Strategy - The company is focused on scaling its healthcare ecosystem, which includes telemedicine, patient record management, and AI-driven care recommendations, by forming strategic alliances with healthcare insurers, third-party administrators, and technology providers [2][4]. - Meridian Group will assist in establishing banking relationships to support HealthLynked's efforts in transforming care management across the healthcare landscape [3]. Leadership and Advisory - David Chua from Meridian Group will lead the advisory effort and has joined HealthLynked as a strategic advisor [3]. - The engagement with Meridian Group is seen as a critical step in increasing market visibility, attracting institutional investors, and evaluating synergistic acquisition opportunities [4]. Market Opportunities - HealthLynked aims to unlock new revenue streams and enhance shareholder value by identifying partners that can drive rapid adoption of its platform through enterprise deployment and vertical integration [4]. - The company sees significant opportunities to deliver value across multiple healthcare sectors, including pharmaceuticals and medical research, leveraging its technology to improve clinical outcomes [4].

Core Insights - Amesite Inc. has launched the NurseMagic™ Enterprise Tier to address the needs of mid- and large-scale post-acute healthcare providers, integrating AI capabilities into existing workflows to enhance operational efficiency and compliance [1][3] - The new pricing model ties costs to patient census rather than headcount, allowing for scalable revenue growth as care delivery expands, which is expected to unlock more opportunities for enterprise adoption [3][4] - NurseMagic™ Enterprise includes features such as seamless EMR integration, automated interdisciplinary team reporting, and custom-formatted documentation, all designed to streamline operations and improve compliance [4][5] Product Features - NurseMagic™ Enterprise enables bi-directional data transfer with EMRs, allowing documentation to populate directly into clinical systems, enhancing documentation efficiency [4] - The platform automates IDT reporting, saving time on compliance processes for home health and hospice agencies without requiring changes to existing team structures [4] - Custom documentation templates are supported, ensuring compliance with payer and regulatory requirements while improving speed and consistency [4] Market Positioning - The launch of NurseMagic™ Enterprise will replace the entry-level B2B Teams plan, offering two tiers: Teams Plus+ for smaller patient censuses and the new Enterprise Tier for larger deployments [3][5] - Amesite aims to capture more value from each organization served, positioning itself for stronger recurring revenue growth through these enhanced offerings [5] - NurseMagic™ is currently utilized across all 50 U.S. states and 21 countries, with a focus on rapid product cycles and sustained growth in the post-acute enterprise market [6][7] Company Overview - Amesite Inc. is an AI-driven company targeting the $330 billion home and healthcare segments, with its flagship product, NurseMagic™, significantly reducing documentation time from 20 minutes to just 20 seconds [7] - The platform is designed to meet HIPAA regulations while improving accuracy and efficiency, serving both B2B and B2C users [7]

The headquarters of Epic, the leading provider of electronic medical records in the U.S., looks nothing like a typical tech campus. It features treehouses, yellow brick roads and sheep fitted with AirTags. (Corrects typo in earlier video, now deleted.) https://t.co/yMzVBxI1eq https://t.co/XL5t2aBqO8 ...

Core Insights - CareCloud, Inc. experienced a stock price increase of approximately 70% in Q2 2025, positioning it among the top gainers in the Russell Microcap Index [1][2] - The company was officially added to the Russell Microcap Index effective June 30, 2025, reflecting its growing visibility and investor confidence [2] - Co-CEO Stephen Snyder highlighted the company's focus on AI innovation, targeted acquisitions, and a strengthened capital structure as key drivers for long-term growth [3] Company Performance - CareCloud's disciplined execution is expected to lead to continued momentum into the second half of 2025 [4] - The company launched a new AI Center of Excellence and resumed M&A activity targeting high-potential verticals [9] - CareCloud completed the conversion of 3.5 million Series A Preferred shares into Common Stock and ended the quarter with over $10 million in cash [9] Company Overview - CareCloud is a leading provider of healthcare technology solutions, offering a comprehensive suite of revenue cycle, practice management, and patient engagement solutions supported by AI technologies [5]

Financial Performance & Guidance - Omnicell预计2020财年产品预订额约为10亿美元[7] - Omnicell预计2020财年总收入为8.9亿至8.92亿美元[7] - Omnicell预计2020财年Non-GAAP EBITDA为1.57亿至1.59亿美元[7] - Omnicell预计2020财年Non-GAAP每股收益为2.46至2.51美元[7] - Omnicell预计2021财年总收入为10.85亿至11.05亿美元[7] - Omnicell预计2021财年Non-GAAP EBITDA为2.28亿至2.4亿美元[7] - Omnicell预计2021财年Non-GAAP每股收益为3.38至3.58美元[7] Growth & Market Position - Omnicell在医疗保健数字化转型中占据领先地位，潜在市场规模超过700亿美元[7, 10] - Omnicell 目标是2021-2025年收入复合年增长率为14-15%（有机增长11-12%，无机增长3%）[7, 10] - Omnicell 目标是从2021-2025年Non-GAAP EBITDA利润率提高约400个基点[7, 10] - Omnicell 目标是SaaS、订阅软件和技术支持服务在2020-2025年的收入复合年增长率约为50%[7, 10]

Company Overview - Clover Health Investments, Corp. is a physician enablement technology company focused on providing access to quality healthcare for Medicare beneficiaries, particularly seniors who have historically faced challenges in accessing affordable healthcare [2] - The company utilizes its software platform, Clover Assistant, to aggregate patient data and support clinical decision-making, aiming to improve health outcomes through early identification and management of chronic diseases [2] - Clover Health offers PPO and HMO Medicare Advantage plans across several states, with a particular emphasis on its wide-network, high-choice PPO plans [2] Upcoming Financial Results - Clover Health will release its financial results for the second quarter of 2025 after market close on August 5, 2025 [1] - A conference call and webcast will be held at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance [1][3] - Investors can access the conference call via telephone or through a live and archived webcast available on the company's Investor Relations website [3]

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care[8] - The company operates a SaaS platform to manage patient intake and offers an integrated patient payments solution[8] - Phreesia processed $1.4 billion in patient payments in FY19[8] - The company serves approximately 1,600 healthcare provider organizations[8, 22] Financial Performance and Market Opportunity - Phreesia's revenue in FY19 was $100 million, demonstrating over 25% growth[8, 9] - The company estimates a total addressable market (TAM) of approximately $7 billion[9] - Subscription and related services accounted for 44% of FY19 revenue, while payment processing contributed 37%, and life sciences 19%[34] - In Q2 2020, total revenue reached $30.8 million, a 24.4% increase compared to Q2 2019[42] Growth Strategy - Phreesia aims to land new clients, grow its footprint within existing clients, and cross-sell new applications[27] - The company focuses on margin expansion through scale and strategic partnerships and M&A[27] - Phreesia achieved a 107% dollar-based net retention rate in FY19[27]

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has been adjour ...